Taiho Oncology and Cullinan Therapeutics Seek FDA Approval for Innovative Lung Cancer Drug Zipalertinib Taiho Oncology and Cullinan Therapeutics have begun filing a New Drug Application for Zipalertinib, aimed at treating advanced non-small cell lung cancer with specific mutations, targeting FDA's accelerated approval pathway.

Taiho Oncology and Cullinan Therapeutics Seek FDA Approval for Innovative Lung Cancer Drug Zipalertinib #USA #Princeton #Taiho_Oncology #Zipalertinib #EGFR_Mutations

Taiho Oncology and Cullinan Unveil Promising Zipalertinib Data for NSCLC at ESMO 2025 At ESMO Congress 2025, Taiho Oncology and Cullinan Therapeutics showcase encouraging findings for zipalertinib in NSCLC patients with brain metastases.

Taiho Oncology and Cullinan Unveil Promising Zipalertinib Data for NSCLC at ESMO 2025 #USA #Princeton #Taiho_Oncology #Cullinan_Therapeutics #Zipalertinib

New Insights on Zipalertinib Efficacy Presented by Taiho Oncology and Cullinan Therapeutics at IASLC 2025 Taiho Oncology and Cullinan Therapeutics unveil promising data on zipalertinib, an oral EGFR inhibitor for lung cancer treatment, at IASLC 2025.

New Insights on Zipalertinib Efficacy Presented by Taiho Oncology and Cullinan Therapeutics at IASLC 2025 #None #Taiho_Oncology #Cullinan_Therapeutics #Zipalertinib

Taiho Oncology Set to Showcase Zipalertinib Data at ESMO 2025 in Berlin Taiho Oncology will present key findings from the REZILIENT2 trial of zipalertinib at ESMO Congress 2025, focusing on NSCLC patients with unique mutations.

Taiho Oncology Set to Showcase Zipalertinib Data at ESMO 2025 in Berlin #None #Berlin #Taiho_Oncology #Zipalertinib #REZILIENT2

Taiho Oncology and Cullinan to Present Zipalertinib Data at IASLC 2025 in Barcelona Discover groundbreaking updates on Zipalertinib from Taiho Oncology and Cullinan Therapeutics at the IASLC 2025 Conference in Barcelona.

Taiho Oncology and Cullinan to Present Zipalertinib Data at IASLC 2025 in Barcelona #United_States #Princeton #Taiho_Oncology #Cullinan_Therapeutics #Zipalertinib

Taiho Oncology and Cullinan Therapeutics Share Promising REZILIENT1 Phase 1/2 Findings on Zipalertinib in Lung Cancer Taiho Oncology and Cullinan Therapeutics have published encouraging results from the REZILIENT1 trial in the Journal of Clinical Oncology, focusing on zipalertinib for lung cancer patients.

Taiho Oncology and Cullinan Therapeutics Share Promising REZILIENT1 Phase 1/2 Findings on Zipalertinib in Lung Cancer #United_States #Taiho_Oncology #Cullinan_Therapeutics #Zipalertinib #Princeton,_New_Jersey

Taiho Oncology Shares Promising Clinical Trial Data at ASCO 2025 Taiho Oncology will present groundbreaking data at the 2025 ASCO meeting, showcasing a novel oral therapy for AML and promising results for NSCLC treatment.

Taiho Oncology Shares Promising Clinical Trial Data at ASCO 2025 #USA #Chicago #Taiho_Oncology #Zipalertinib #ASCO_2025

Taiho Oncology To Present Exciting New Clinical Data at ASCO 2025 Annual Meeting Taiho Oncology is set to present groundbreaking data at the 2025 ASCO Annual Meeting, featuring two oral discussions on innovative cancer treatments.

Taiho Oncology To Present Exciting New Clinical Data at ASCO 2025 Annual Meeting #United_States #Chicago #Taiho_Oncology #Zipalertinib #ASCO_2025

Clinical Breakthrough: Zipalertinib Shows Promise for Patients with NSCLC in Recent Phase Trial Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics celebrate a successful Phase 2b trial of Zipalertinib for NSCLC patients, expanding treatment options.

Clinical Breakthrough: Zipalertinib Shows Promise for Patients with NSCLC in Recent Phase Trial #Japan #Tokyo #Taiho_Oncology #Cullinan_Therapeutics #Zipalertinib